Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Seattle Genetics Climbed 17.6% in September

By Brian Orelli, PhD - Oct 7, 2019 at 8:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Data from a pair of clinical trials sent shares of the oncology drugmaker higher.

What happened

Shares of Seattle Genetics (SGEN -1.37%) jumped 17.6% in September, according to data provided by S&P Global Market Intelligence, as the biotech rounded out the month with positive data from a pair of clinical trials presented at the 2019 European Society for Medical Oncology (ESMO) Congress.

So what

In a phase 2 clinical trial, Seattle Genetics' tucatinib combined with Roche's Herceptin produced a response in 52.2% of patients with a specific type of late-stage colorectal cancer. There wasn't a control group that received placebo or an alternative drug, but these patients had already failed two treatments, so over half of the 23 patients responding was quite impressive.

Doctor talking to a patient in front of a window.

Image source: Getty Images.

The second ESMO presentation was for an early stage study testing Seattle Genetics' enfortumab vedotin (EV) with Merck's (MRK -0.25%) Keytruda in patients with previously untreated, locally advanced, or metastatic urothelial cancer who can't take a chemotherapy called cisplatin. The combination produced a response in 71% of the patients, including 13% with a complete response and 58% with a partial response.

The second study didn't have a control, either, but a clinical trial run by Merck testing Keytruda as a monotherapy in similar patients produced a response rate of 29%. Even in patients with high expression of PD-L1, the pathway that Keytruda targets, the response rate was only 47%, so adding EV seems to be substantially increasing the efficacy.

Now what

Seattle Genetics will likely have to test EV plus Keytruda in an additional clinical trial before gaining regulatory approval in newly diagnosed urothelial cancer patients, but EV is already under FDA review for patients with late-stage urothelial cancer who have received a PD-1/L1 inhibitor, such as Keytruda. Assuming the drug is approved, which seems likely, some doctors may use it off-label for previously untreated patients, or, at the very least, the ESMO data offer additional efficacy evidence that should persuade doctors to use the drug on late-stage patients.

Tucatinib is also being tested in patients with metastatic breast cancer in the Her2Climb clinical trial that should be sufficient to gain regulatory approval if the data are positive. In addition to expanding the potential market, the colorectal cancer data provide additional evidence that tucatinib is working, which should give biotech investors increased confidence in a positive outcome for the Her2Climb study.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
$168.45 (-1.37%) $-2.34
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$90.81 (-0.25%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.